GLP‐1 receptor agonists, PPAR‐γ‐agonists, SGLT2‐inhibitors may all be preferred pharmacological interventions for patients with MASLD/MASH and T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.